Task: Answer Verification
Input (English): Question: Does homocysteine-lowering treatment with folic acid , cobalamin , and pyridoxine reduce blood markers of inflammation , endothelial dysfunction , or hypercoagulability in patients with previous transient ischemic attack or stroke : a randomized substudy of the VITATOPS trial?
Answer: Lowering tHcy by 3.7 micromol/L with folic acid-based multivitamin therapy does not significantly reduce blood concentrations of the biomarkers of inflammation, endothelial dysfunction, or hypercoagulability measured in our study. The possible explanations for our findings are: (1) these biomarkers are not sensitive to the effects of lowering tHcy (eg, multiple risk factor interventions may be required); (2) elevated tHcy causes cardiovascular disease by mechanisms other than the biomarkers measured; or (3) elevated tHcy is a noncausal marker of increased vascular risk.
Output (English): no